Literature DB >> 1839313

Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly.

P V Colthup1, C C Felgate, J L Palmer, N L Scully.   

Abstract

Ondansetron is a 5-hydroxytryptamine3 receptor antagonist for the treatment of chemotherapy- and radiotherapy-induced nausea and emesis. A sensitive, accurate, and precise HPLC method for the determination of ondansetron in plasma is described. Samples are prepared by solid-phase extraction and, after chromatography of the extracts on a silica analytical column, ondansetron is detected by UV absorbance at 305 nm. The method is sensitive down to 1 ng/mL, at which concentration the coefficient of variation was 6.2% in a single assay run. Repeated analyses of quality control samples, nominally at 2 ng/mL, were carried out over a number of assay runs with a coefficient of variation of 5.5%. The method is specific for ondansetron with respect to endogenous plasma components, identified phase I metabolites, and some co-administered chemotherapeutic drugs. In sustained use over several months, and in support of the clinical development of ondansetron, the method has been shown to be robust. An application of the assay in the investigation of the pharmacokinetics of ondansetron in the young and elderly is described.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1839313     DOI: 10.1002/jps.2600800913

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  17 in total

1.  A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.

Authors:  E H Cox; C Veyrat-Follet; S L Beal; E Fuseau; S Kenkare; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

2.  PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.

Authors:  Rachel Huddart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-06       Impact factor: 2.089

3.  Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers.

Authors:  L S Gan; P H Hsyu; J F Pritchard; D Thakker
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

4.  Simultaneous quantification of ondansetron and tariquidar in rat and human plasma using a high performance liquid chromatography-ultraviolet method.

Authors:  Yae Eun Chong; Manting Chiang; Kiran Deshpande; Simon Haroutounian; Leonid Kagan; Jong Bong Lee
Journal:  Biomed Chromatogr       Date:  2019-09-01       Impact factor: 1.902

5.  Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.

Authors:  Larry F Chu; John Sun; Anna Clemenson; Matthew J Erlendson; Tom Rico; Erika Cornell; Hannah Obasi; Zahra N Sayyid; Ellen M Encisco; Jeff Yu; Jamison G Gamble; Ian Carroll; J David Clark
Journal:  J Addict Med       Date:  2017 Sep/Oct       Impact factor: 3.702

6.  Population pharmacokinetics of ondansetron: a covariate analysis.

Authors:  D P de Alwis; L Aarons; J L Palmer
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

7.  The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.

Authors:  J C Blake; J L Palmer; N A Minton; A K Burroughs
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 8.  Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony Markham; Eugene M Sorkin
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 9.  Ondansetron clinical pharmacokinetics.

Authors:  F Roila; A Del Favero
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

10.  Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum.

Authors:  P H Hsyu; J F Pritchard; H P Bozigian; T L Lloyd; R H Griffin; R Shamburek; G Krishna; W H Barr
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.